How Viral Infections Trigger Bladder Cancer via APOBEC3 Mutations
New research reveals viruses activate APOBEC3 enzymes in normal bladder cells, seeding the cancer-causing mutations seen in tumors.
Summary
Researchers demonstrated that common viral infections can hijack the APOBEC3 family of DNA-editing enzymes in normal human urothelial cells, generating the characteristic C-to-T and C-to-G mutations (SBS2, SBS13) found in bladder cancer. Using normal bladder cell cultures infected with HPV16 and BK polyomavirus, they showed APOBEC3A and APOBEC3B are strongly induced by viral infection, driving mutagenesis at TC motifs in cancer-relevant genes including TP53, FGFR3, and PIK3CA. Crucially, this occurred in histologically normal, pre-malignant tissue, suggesting viruses may act as early initiators of bladder cancer rather than merely passengers in established tumors.
Detailed Summary
Bladder cancer carries one of the highest mutation burdens of any cancer, and APOBEC3-signature mutations (mutational signatures SBS2 and SBS13) account for a large proportion of these changes—yet the trigger for APOBEC3 hyperactivation has remained unclear. This study provides compelling experimental evidence that viral infection of normal human urothelial cells is sufficient to initiate this mutagenic process before any malignant transformation occurs.
The research team, led by Simon Baker at the University of York, used a well-characterized normal human urothelial (NHU) cell culture system that faithfully recapitulates the urothelial differentiation state. Cells were infected with two clinically relevant viruses: HPV16 (a high-risk human papillomavirus) and BKPyV (BK polyomavirus, commonly reactivated in immunosuppressed patients such as kidney transplant recipients). Gene expression, protein levels, and mutational signatures were assessed in infected versus control cells using RNA sequencing, western blotting, flow cytometry, and whole-genome or targeted sequencing.
Key results showed that both HPV16 and BKPyV infection potently upregulated APOBEC3A and APOBEC3B mRNA and protein in NHU cells. This induction was accompanied by a significant increase in TC-context cytosine deamination activity, the biochemical hallmark of APOBEC3 action. Whole-genome sequencing of virally infected NHU cell cultures revealed accumulation of SBS2- and SBS13-like mutations, particularly enriched at TC dinucleotide motifs. Strikingly, mutations were detected in driver genes for bladder cancer including TP53, FGFR3, and PIK3CA—genes mutated early in bladder carcinogenesis. The study also analyzed sequencing data from normal urothelium of kidney transplant recipients (who have high rates of BKPyV reactivation) and found elevated APOBEC3-signature mutations compared to immunocompetent controls, linking in vitro findings to in vivo human tissue.
The implications are significant. This work shifts the framing of APOBEC3 mutagenesis in bladder cancer from a consequence of tumor evolution to a potential initiating cause, with viral infection as a plausible environmental trigger. It may explain why bladder cancer risk is elevated in certain immunosuppressed populations and offers a new mechanistic link between viral urinary tract infections and cancer development. The findings also raise the possibility that antiviral strategies or APOBEC3 inhibitors could serve as cancer prevention tools in high-risk individuals.
Important caveats remain. The cell culture model, while biologically relevant, does not fully replicate the complex immune microenvironment of intact urothelium. Causality between viral infection, APOBEC3 induction, and eventual tumor formation in humans has not been proven in longitudinal cohorts. Additionally, the contribution of other viruses or cofactors (smoking, chemical carcinogens) to APOBEC3 activation in bladder cancer was not explored, and the relative risk attributable to viral-APOBEC3 mutagenesis versus other etiological pathways remains to be quantified.
Key Findings
- HPV16 and BKPyV infection of normal urothelial cells strongly induces APOBEC3A and APOBEC3B expression.
- Virally infected normal bladder cells accumulate SBS2/SBS13 APOBEC3-signature mutations at TC motifs.
- Driver gene mutations (TP53, FGFR3, PIK3CA) arise in virally infected pre-malignant urothelial cells.
- Normal urothelium from kidney transplant recipients shows elevated APOBEC3-signature mutations in vivo.
- Viral APOBEC3 induction may initiate bladder cancer before any morphological transformation occurs.
Methodology
Normal human urothelial (NHU) cell cultures were infected with HPV16 or BKPyV and assessed by RNA-seq, western blotting, and deaminase activity assays. Whole-genome and targeted sequencing identified mutational signatures in infected cells and in urothelial tissue from kidney transplant recipients. Mutational signature analysis used COSMIC reference signatures SBS2 and SBS13.
Study Limitations
Cell culture models lack the immune microenvironment of intact urothelium, and a direct causal chain from viral infection to frank malignancy in humans remains unproven. The relative contribution of viral-driven APOBEC3 mutagenesis versus other bladder carcinogens (tobacco, occupational exposures) was not compared. Longitudinal cohort data linking viral infection to APOBEC3-signature bladder tumors are needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: